COVID-19 in patients with haematologic malignancies: Effect of RNAemia on clinical outcome in vaccinated patients

Patients with haematologic malignancies (HM) COVID-19 have more severe disease, with increased risk of mortality. Therefore, this study aimed to evaluate the effect of SARS-CoV-2 RNAemia and the specific humoral immune responses on the clinical outcomes of patients with HM and COVID-19.

Detalhes bibliográficos
Autores: Martín-Escolano, Javier, Salto-Alejandre, Sonsoles, Infante-Domínguez, Carmen, Carretero-Ledesma, Marta, Maldonado-Lizarazo, Natalia, Camacho-Martínez, Pedro, Martín-Domínguez, Francisco, Tallón-Ruiz, Inmaculada, Ruiz-Molina, Ana, Palacios-Baena, Zaira Raquel, Pérez-Palacios, Patricia, Paniagua-García, María, Álvarez-Marín, Rocío, Merino, Laura, Cisneros, José Miguel, Cordero, Elisa, Pachón, Jerónimo, Pérez-Simón, José A., Sánchez-Céspedes, Javier, Aguilar-Guisado, Manuela
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/368562
Acesso em linha:http://hdl.handle.net/10261/368562
https://api.elsevier.com/content/abstract/scopus_id/85199331535
Access Level:acceso abierto
Palavra-chave:COVID-19
Clinical outcome
Haematologic malignancies
RNAemia
SARS-CoV-2
Descrição
Resumo:Patients with haematologic malignancies (HM) COVID-19 have more severe disease, with increased risk of mortality. Therefore, this study aimed to evaluate the effect of SARS-CoV-2 RNAemia and the specific humoral immune responses on the clinical outcomes of patients with HM and COVID-19.

Registos relacionados